ARTICLE | Financial News
Ambrx sets IPO range
June 10, 2014 12:09 AM UTC
Ambrx Inc. (La Jolla, Calif.) amended its IPO on NASDAQ and now plans to sell 5.4 million shares at $12-$14. At the $13 midpoint, the company would raise $70.2 million and be valued at $223.2 million. Stifel; Wells Fargo Securities; Canaccord; Needham; and Roth Capital Partners are underwriters. Ambrx is developing a pipeline of antibody-drug conjugates by engineering non-native amino acids into mAbs via site-specific conjugation. The company is also developing bispecific and multi-specific drug conjugates and long-acting proteins. ...